OptimizeRx Reports Q3 2026 Growth in Adjusted EBITDA Amid Revenue Pressures
OptimizeRx (OPRX) reported third-quarter 2026 financial results characterized by significant margin expansion despite revenue headwinds. The company achieved an adjusted EBITDA of $6.3 million, a notable increase from $5.1 million in the prior year, driven by strong gross margins and effective cost management initiatives. Adjusted EBITDA margins rose to 29%, up over 900 basis points year-over-year. However, revenue reached $21.6 million, impacted by reduced spending among a small group of large customers and market uncertainty regarding Most Favored Nation (MFN) pricing. While net revenue retention declined to 83% due to customer spend optimization, the company noted a positive outlook for 2027, with contracted revenue trending 20% ahead of the previous year. Management cautioned that meeting full-year guidance will require significant business conversions in the fourth quarter.
Tickers: $OPRX
Topics: Adjusted EBITDA Guidance Net Income Net Revenue Retention Revenue